Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection

Bibliography

• ADKINS JC, NOBEL S: Efavirenz. Drugs. (1998) 56:1055–1064.
   PubMed Web of Science ®Google Scholar
• SCOTT LJ, PERRY M: Delavirdine. A Review of its use in HIV Infection. Drugs. (2000) 60:1411–1444.
   Google Scholar
• TRAN JQ, GERBER JG, KERR BM: Delavirdine: clinical pharmacokinetics and drug interactions. Abstract. Clin. Pharmatvkinet. (2001) 40:207–226.
   Google Scholar
• BARDSLEY-ELLIOT A, PERRY CM: Nevirapine: a review of its use in the prevention and treatment of pediatric HIV infection. Pediatric Drugs (2000) 2:373–407.
   PubMedGoogle Scholar
• ERICK DE CLERCQ: Novel compounds in preclinicaYearly clinical development for the treatment of HIV infections. Rev Med. Viral (2000) 10:255–277.
   PubMed Web of Science ®Google Scholar
• CORBETT JW, KO SS, RODGERS JD, et al.: Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. Med. Chem. (2000) 43:2019–2030.
   Google Scholar
• CORBETT JW, KO SS, RODGERS JD et al.: Expanded-spectrum non-nucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrab. Agents Chemather. (1999) 43:2893–2897.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev (19960 16:125–157.
   Google Scholar
• DE CLERCQ E: What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Med. Virology (1996) 6:97–117.
   Web of Science ®Google Scholar
• DE CLERCQ E: The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. (1998) 38:153–179.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. IL Farmatv (1999) 54:26–45.
   PubMedGoogle Scholar
• MOYLE G: The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs. (2001) 61:19–26.
   PubMed Web of Science ®Google Scholar
• BACK NK, BERKHOUT B: Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1997) 41:2484–2491.
   PubMed Web of Science ®Google Scholar
• GOSSELIN G, SCHINAZI SOMMADOSSI JP et al.: Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. (1994) 38:1292–1297.
   Google Scholar
• LIN TS, LUO MZ, LIU MC, PAI SB, DUTSCHMAN GE, CHENG YC: Synthesis and antiviral evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides with an improved in vitro therapeutic index against hepatitis B and human immunodeficiency virus (Meeting abstract). Proc. Aram. Meet. Am. Assoc. Cancer Res. (1994) 35:A1848.
   Google Scholar
• BABA M, TANAKA H, DE CLERCQ E et al.: Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biachem.Biaphys.Res.Commun. (1989) 165:1375–1381.
   Google Scholar
• PAUWELS R, ANDRIES K, DESMYTER J et al.: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 343:470–4.
   PubMed Web of Science ®Google Scholar
• ARRANZ E, DIAZ JA, INGATE ST et al.:Novel 1, 1,3-trioxo-2H,4H-thieno [3,4-e] [1,2,41thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. I Med. Chem. (1998) 41:4109–4117.
   PubMed Web of Science ®Google Scholar
• WITVROUW M, ARRANZ ME, PANNECOUQUE C et al.: 1,1,3-Trioxo-2H,4H-thieno [3,4-e] [1, 2,4[thiadiazine (TTD) derivatives: a net of non-nucleoside human immunodeficiency virus type 1(HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrob. Agents Chemother. (1998) 42:618–623.
   PubMed Web of Science ®Google Scholar
• 12th International Conference on AntiviralResearch. Jerusalem, Israel. Mar 25 (1999). Abstracts. Antiviral Res. (1999) 41:A31–A75.
   Google Scholar
• FUJI WARA T, SATO A, EL-FARRASH Met al.: S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (1998) 42:1340–1345.
   Google Scholar
• WISHKA DG, GRABER DR, KOPTA LA etal.: 0-6-Chloro-2- [ (1-furo [2, 3-Hpyridin-5-ylethyl)thicd -4-pyrimidinamine, PM 142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. j Med. Chem. (1998) 41:1357–1360.
   Google Scholar
• MAO C, SUDBECK EA, VENKATACHALAM TK, UCKUN FM: Rational design of N- [242,5-dimethoxyphenylethyl)[-N'- [2- (5-bromopyridithiourea HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioarg. Med. Chem. (1999a) 9:1593–1598.
   Web of Science ®Google Scholar
• MAO C, SUDBECK EA, VENKATACHALAM TK, UCKUN FM: Structure-based design of non-nucleoside reverse transcriptase inhibitors of resistant human immunodeficiency virus. Antiviral Chem. Chemother. (1999b) 10:233–240.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, CROWE S, LEVY J et al.: Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. j Infect. Dis. (1988) 158:862–865.
   PubMed Web of Science ®Google Scholar
• VIG R, MAO C, VENKATACHALAM TK, TUEL-AHLGREN L, SUDBECK EA, UCKUN FM: 5-Alky1-2-Rmethylthiomethyl)thiol-6-(benzy1)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioarg. Med. Chem. Lett. (1998) 8:1461–1466.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: HIV resistance to reverse transcriptase inhibitors. Biochem. PharmacaL (1994) 47:155–169.
   PubMed Web of Science ®Google Scholar
• DEEKS SG: Non-nucleoside Reverse Transcriptase Inhibitor Resistance. I Acquir. Immune. Defic. Syndr. (2001) 26\(Suppl. 1):S25–S33.
   Google Scholar
• SCHINAZI RF, LARDER BA, MELLORS JW: Mutations in retroviral genes associated with drug resistance. International Antiviral News (1996) 4:95–107.
   Google Scholar
• BUCKHEIT JRRW, FLIAKAS-BOLTZ V, RUSSELL JD etal.: SJ-3366, a unique and highly potent non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) thal also inhibits HIV-2. Antimicrobial Agents and Chemotherapy (2001) 45:393–400.
   Google Scholar
• DE CLERCQ E: Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaca (1999) 54:26–45.
   PubMedGoogle Scholar
• COHEN KA, HOPKINS J, INGRAHAM RH et al.: Characterization of the binding site for nevirapine (BI-RG-587), a non-nucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. j Biol. Chem. (1991) 266:14670–14674.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, EMINI EA, GOTLIB Let al.: Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse non-nucleoside inhibitors. Antimicrob. Agents Chemother. (1992) 36:1441–1446.
   Google Scholar
• GROB PM, WU JC, COHEN KA et al.: Non-nucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses. (1992) 8:145–152.
   PubMed Web of Science ®Google Scholar
• SMERDON SJ, JAGER J, WANG J et al.:Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Li. USA (1994) 91:3911–3915.
   PubMed Web of Science ®Google Scholar
• JACOBO-MOLINA A, ARNOLD E: HIV Reverse transcriptase structure-function Relationships. Biochemistry (1991) 30:6351–6361.
   PubMed Web of Science ®Google Scholar
• KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ TA: Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
   Google Scholar
• NANNI RG, DING J, JACOBO-MOLINA A, HUGHES SH, ARNOLD E: Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspect.Drug Discovery Design. (1993) 1:129–150.
   Google Scholar
• TANTILLO C, DING J, JACOBO-MOLINA A et al.: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. j Mal. Biol. (1994) 243:369–387.
   Google Scholar
• BARBER AM, HIZI A, MAIZEL JV, JR., HUGHES SH: HIV-1 reverse transcriptase: structure predictions for the polymerase domain. AIDS Res. Hum. Retroviruses. (1990) 6:1061–1071.
   PubMed Web of Science ®Google Scholar
• NUNBERG JH, SCHLEIF WA, BOOTS EJ etal.: Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Viral. (1991) 65:4887–4892.
   Google Scholar
• WITVROUW M, PANNECOUQUE C, VAN LAETHEM K, DESMYTER J, DE CLERCQ E, VANDAMME A: Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS (1999) 13:1477–1483.
   PubMed Web of Science ®Google Scholar
• RUSSELL JD: The role of in-vitro combination efficacy evaluation to prioritize anti-HIV compounds for clinical trials. Thesis Dissertation, Hood College, Frederick, MD (1999)
   Google Scholar
• BUCKHEIT RW, JR., FLIAKAS-BOLTZ V, YEAGY-BARGO S et al: Resistance to 1-R2-Hydroxyethoxy)methyll-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology (1995) 210:186–193.
   PubMed Web of Science ®Google Scholar
• BUCKHEIT RW JR., HOLLINGSHEAD MG, GERMANY et al: Thiazolobenzimidazole: biological and biochemical anti- retroviral activity of a new non-nucleoside reverse transcriptase inhibitor. Antiviral Res. (1993) 21:247–265.
   PubMed Web of Science ®Google Scholar
• BUCKHEIT RW JR, KINJERSKI TL, FLIAKAS-BOLTZ V et al.: Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. (1995) 39:2718–2727.
   PubMed Web of Science ®Google Scholar
• ESNOUF R, REN J, ROSS C, JONES Y, STAMMERS D, STUART D: Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Struct. Biol. (1995) 2:303–308.
   Google Scholar
• BARNARD J, BORKOW G, PARNIAK MA: The thiocarboxanilide non-nucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry (1997) 36:7786–7792.
   PubMed Web of Science ®Google Scholar
• FLETCHER RS, ARION D, BORKOW G, WAINBERG MA, DMITRIENKO GI, PARNIAK MA: Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide non-nucleoside compounds. Biochemistry (1995) 34:10106–10112.
   PubMed Web of Science ®Google Scholar
• FLETCHER RS, SYED K, MITHANI S, DMITRIENKO GI, PARNIAK MA: Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry (1995) 34:4346–4353.
   PubMed Web of Science ®Google Scholar
• BUCKHEIT RW JR, FLIAKAS-BOLTZ V,DECKER WD et al.: Comparative anti- HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. (1995) 26:117–132.
   Google Scholar
• LOFTUS TL: Relative replication competence of virus isolates resistant to anti-HIV compounds. Thesis Dissertation, Hood College, Frederick, MD (2000).
   Google Scholar
• LEE K, GULICK RM: New drugs for the treatment of HIV infection. Curr. Infect. Dis. Rep. (2001) 3:193–200.
   PubMedGoogle Scholar
• XU G, MICKLATCHER M, SILVESTRI MA et al.: The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. j Med. Chem. Submitted (2001).
   Google Scholar
• BUCKHEIT JR RW, WHITE EL, FLIAKAS-BOLTZ V et al.: Unique anti-human immunodeficiency virus activities of the non-nucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob. Agents Chemother. (1999) 43:827–1834.
   Google Scholar
• CURRENS MJ, GULAKOWSKI RJ, MARINER JM et al.: Antiviral activity mechanism of action of calanolide A against the human immunodeficiency virus. Pharmacol Exptl. Ther. (1996) 279:645–651.
   PubMed Web of Science ®Google Scholar
• CURRENS MJ, MARINER JM, MCMAHON JB, BOYD MR: Kinetic analysis of inhibition of human immunodeficiency virus type 1 reverse transcriptase by calanolide A. j Pharmacol Exp. Ther. (1996) 279:652–661.
   PubMed Web of Science ®Google Scholar
• BOYER PL, CURRENS MJ, MCMAHON JB, BOYD MR, HUGHES SH: Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.Viral. (1993) 67:2412–2420.
   PubMed Web of Science ®Google Scholar
• BOYER PL, GAO H, HUGHES SH: A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. (1998) 42:447–452.
   PubMed Web of Science ®Google Scholar
• BOYER PL, TANTILLO C, JACOBO-MOLINA A et al.: Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistnat mutants does not. Proc. Natl. Acad. Sri. USA (1994) 91:4882–4886.
   PubMed Web of Science ®Google Scholar
• DEMETER L: HIV reverse transcriptase with non-nucleoside inhibitor resistance mutations demonstrate abnormalities in RNase H cleavage. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA. Abstract No.2(1999)
   Google Scholar
• BOYER PL, HUGHES SH: Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (1995) 39:1624–1628.
   PubMed Web of Science ®Google Scholar
• SHAFER RW, WINTERS MA, IVERSEN AK, MERIGAN TC: Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (1996) 40:2887–2890.
   PubMed Web of Science ®Google Scholar
• GERONDELIS P, ARCHER RH, PALANIAPPAN C et al: The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. j Viral. (1999) 73:5803–5813.
   PubMed Web of Science ®Google Scholar
• BUCKHEIT JR RW, HOLLINGSHEAD M, STINSON S et al: Efficacy, pharmacokinetics and in vivo antiviral activity of UC781, a highly potent, orally bioavailable non-nucleoside reverse transcriptase inhibitor of HIV-1. Submitted (1996).
   Google Scholar
• TURPIN J, LOFTUS TL, WARGO H et al.: Structure-activity relationships of SJ-3366 (2,4 (1H,3H)-pyrimidinediones): inhibition of reverse transcriptase, virus attachment and HIV-1 and HIV-2 replication. Antiviral Res. (2001) 50:A40
   Google Scholar
• LAWLESS MK, BARNEY S, GUTHRIE KI, BUCY TB, PETTEWAY JR. SR, MERUTKA G: HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Abstract. Biochemistry (1996) 35:13697–13708.
   Google Scholar
• KIMPTON J, EMERMAN M: Detection of replication-competent and pseudotyped HIV with a sensitive cell line based on activitation of an integrated I3-galactosidase gene. I Viral. (1992) 66:2232–2239.
   PubMed Web of Science ®Google Scholar
• LOI AG, COSTI R, ARTICO M et al: 5-Arylthiopyroles (ATPs) a new class of potent NNRTIs active against wild type and resistant strains of HIV-1. Antiviral Res. (2001) 50:A48
   Google Scholar
• BUCKHEIT JR RW, SNOW MJ, FLIAKAS-BOLTZ V et al: Highly potent oxathiin carboxanilide derivatives with efficacy against human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor-resistant virus isolates. Antimicrob. Agents Chemother. (In press) (1997).
   Google Scholar
• MCMAHON JB, BUCKHEIT RW JR, GULAKOWSKI RJ et al: Biological and biochemical anti-human immunodeficiency virus activity of UC-38, a new non-nucleoside reverse transcriptase inhibitor. Pharmacol Exp. Ther. (1995) 276:298–305.
   Web of Science ®Google Scholar
• BALZARINI J, NAESENS L, VERBEKEN E et al: Preclinical Studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS (1998) 12:1129–1138.
   PubMed Web of Science ®Google Scholar
• BALZARINI J, PELEMANS H, ESNOUF R, DE CLERCQ E: A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the non-nucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res. Hum. Retroviruses. (1998) 14:255–260.
   PubMed Web of Science ®Google Scholar
• BORKOW G, ARION D, WAINBERG MA, PARNIAK MA: The thiocarboxanilide non-nucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (1999) 43.
   Google Scholar
• BORKOW G, BARNARD J, NGUYEN TM, BELMONTE A, WAINBERG MA, PARNIAK MA: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide non-nucleoside inhibitor of HIV-1 reverse transcriptase. Viral (1997) 71:3023–3030.
   PubMed Web of Science ®Google Scholar
• KINJERSKI TL, BUCKHEIT RW JR: Therole of genotypic heterogeneity in wild type virus populations on the selection of non-nucleoside reverse transcriptase inhibitor-resistance viruses. Antiviral Res. (1997) 33:109–115.
   PubMed Web of Science ®Google Scholar
• KINJERSKI TL, PALLANSCH LA, BUCKHEIT RW JR: Isolation and characterization of HIV-1 isolates resistant to oxathiin carboxanilide analogs: evaluation of variables in the resistance selection process. Antiviral Chemistry & Chemotherapy (1996) 7:261–269.
   Web of Science ®Google Scholar
• BALZARINI J: Preclinical properties of the thiocarboxanilide UC-781 as a potential virucidal compound against HIV. AIDS (2001) 15\(Suppl. 1):S38–S39.
   Google Scholar
• PARNIAK MA: Non-nucleoside reverse transcriptase inhibitors as anti-HIV-1 microbicides. AIDS (2001) 15 (Suppl. I).
   Google Scholar
• QUAN Y, MOTAKIS D, BUCKHEIT RW JR et al:. Sensitivity and resistance to (-0-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antiviral Therapy (1999) 4:203–209.
   Google Scholar
• STEIN CA, MATSUKURA M, SUBASINGHE C, BRODER S, COHEN JS: Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res. Hum. Retroviruses. (1989) 5:639–646.
   PubMed Web of Science ®Google Scholar
• BLAIR WS, SATO A, SUGIMOTO H etal.: Resistance and cross-resistance profiles of capravirine, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Antiviral Res. (2001) 50:A52
   Google Scholar
• LEAVITT MC, BANH V, GRAHAM J etal.: In vitro antiviral studies of the HIV-1 non-nucleoside reverse transcriptase inhibitor, capravirine, alone and in combination with HIV-1 protease inhibitors. Antiviral Res. (2001) 50:A48
   Google Scholar
• REN J, NICHOLS C, BIRD LE et al: Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. j Biol. Chem. (2000) 12:275–
   Google Scholar
• GUAY LA, MUSOKE P, FLEMING T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 354:795–802.
   PubMed Web of Science ®Google Scholar
• BUCKHEIT JR RW: In vitro strategies forthe preclinical development of topical microbicides: classes of potential inhibitors. AIDS (2001) 15 (Suppl. 1):537–538.
   Google Scholar
• HU J, POPE M, BROWN C, O'DOHERTY U, MILLER CJ: Immunophenotypic characterization of simian immunodeficiency virus-infected dendritic cells in cervix, vagina, and draining lymph nodes of rhesus monkeys. Lab. Invest. (1998) 78:435–451.
   PubMed Web of Science ®Google Scholar
• STAHL-HENNIG C, STEINMAN RIVI, TENNER-RACZ K et al.: Rapid infection of oral mucosal-associated lumphoid tissue with simian immunodeficiency virus. Science (1999) 285:1261–1265.
   PubMed Web of Science ®Google Scholar